ID   RERF-LC-FM
AC   CVCL_1653
SY   LC-FM; RERFLCFM; Radiation Effects Research Foundation-Lung Cancer-FM
DR   BioSample; SAMN03471072
DR   CCLE; RERFLCFM_LUNG
DR   Cell_Model_Passport; SIDM00357
DR   Cosmic; 713884
DR   Cosmic; 929161
DR   Cosmic; 930081
DR   Cosmic; 1995618
DR   Cosmic-CLP; 930081
DR   DepMap; ACH-002193
DR   GEO; GSM1670371
DR   JCRB; JCRB0102
DR   PharmacoDB; RERFLCFM_1304_2019
DR   Wikidata; Q54949761
RX   PubMed=8286010;
RX   PubMed=9290701;
RX   PubMed=9413215;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 58.9 hours (PubMed=8286010); 60 hours (lot 101698) (JCRB).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Genome ancestry: African=0.25%; Native American=0%; East Asian, North=77.86%; East Asian, South=20.45%; South Asian=0.87%; European, North=0%; European, South=0.57% (PubMed=30894373).
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 11
ST   D5S818: 10
ST   D7S820: 11,12
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 18,19
DI   NCIt; C4917; Small cell lung carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 20
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9413215;
RA   Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K.,
RA   Hiraki A., Ueoka H., Harada M.;
RT   "Small cell lung cancer can express CD34 antigen.";
RL   Anticancer Res. 17:3627-3632(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//